Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0684249 (lung carcinoma)
 23,830 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of hypertrophic osteoarthropathy associated with carcinoma of the lung is presented. The symptomatology of the former usually dominates the clinical picture so that early diagnosis of the underlying carcinoma often depends on recognition of hypertrophic osteoarthropathy. A brief review of the literature is given.
 ...
PMID:Hypertrophic osteoarthropathy--an important differential diagnosis. 91 38

The relationship of periostitis to disease duration in primary hypertrophic osteoarthropathy and the association of periostitis with cardiopulmonary disorders (secondary type) were studied in order to define distinguishing features between the two. Radiographic skeletal surveys were performed in 24 patients with hypertrophic osteoarthropathy to analyze pattern (single layer, multilayered, irregular) and site of involvement (diaphysis, metaphysis, epiphysis). The six patients with primary hypertrophic osteoarthropathy and the 11 patients with cyanotic congenital heart disease had thicker, more widespread periostitis involving the diaphysis, metaphysis, and epiphysis, in contrast to abnormalities in the seven patients with hypertrophic osteoarthropathy secondary to carcinoma of the lung. Average cortical bone widths as determined by radiogrammetric measurement of the second metacarpals were significantly greater for the patients with primary hypertrophic osteoarthropathy (8.9 +/- 6.0 mm) and cyanotic congenital heart disease (8.5 +/- 6.4 mm) as compared with the patients with bronchogenic carcinoma (6.0 +/- 3.9 mm). Correlation of radiographic patterns with duration of disease confirms that thicker, more extensive alterations are indicative of long-standing disease. The periostitis of hypertrophic osteoarthropathy is therefore not dependent on the primary or secondary nature of the disease but principally on its duration.
 ...
PMID:Periostitis in hypertrophic osteoarthropathy: relationship to disease duration. 349 63

A case of autonomic neuropathy and hypertrophic osteoarthropathy in association with metastatic giant cell carcinoma of the lung and leiomyosarcoma of the stomach is reported. The link between these conditions is discussed and the role of pancreatic polypeptide as a possible marker for hypertrophic osteoarthropathy reported.
 ...
PMID:Autonomic neuropathy and hypertrophic osteoarthropathy in association with malignancy. 405 12

A group of 100 patients with carcinoma of the lung underwent an examination for metastatic spread; evaluation of the bone scans taken at that time showed that 4 of these patients had the clinical and scintigraphic symptoms of hypertrophic osteoarthropathy. Roentgenological abnormalities were evident in 3 of these 4 cases. The diverse scintigraphic patterns characteristic of hypertrophic osteoarthropathy are discussed. Follow-up bone scans taken after initiation of therapy were used to investigate the changes in the scintigraphic patterns in 3 patients. Improvement was seen within 2 months. Clinical improvement preceded improvement on the scan; radiological improvement however, occurs later than that seen on the bone scan.
 ...
PMID:Bone scintigraphy for the detection and follow-up of hypertrophic osteoarthropathy. 680 Jul 46

A patient with hypertrophic osteoarthropathy (HO) secondary to large cell anaplastic carcinoma of the lung was treated with combination chemotherapy (CAP-1). Systemic tumor symptoms resolved within 3 wk. Relief from the bone and articular symptoms of HO was noted after 3 months of treatment, coincident with a partial remission (greater than 50% tumor regression). Objective improvement in the radionuclide bone scan and radiographic periostitis was demonstrated after 6 months. Symptomatic improvement continued despite evidence of tumor progression after 10 months of treatment. Systemic chemotherapy should be considered in the management of symptomatic osteoarthropathy secondary to unresectable bronchogenic carcinoma.
 ...
PMID:Reversal of hypertrophic osteoarthropathy after chemotherapy for bronchogenic carcinoma. 735 75

In a 49-year-old man, large-cell carcinoma of the lung was accompanied by raised serum levels of growth hormone (GH) and growth hormone-releasing hormone (GHRH) and hypertrophic osteoarthropathy. Immunohistochemically the tumour contained GHRH but not GH. The osteoarthropathy disappeared after resection of the primary tumour and did not reappear after its recurrence. The high serum GH level presumably was due to ectopic GHRH production in the tumour. The hypertrophic osteoarthropathy was not clearly attributable to these hormones.
 ...
PMID:Lung cancer containing growth hormone-releasing hormone associated with hypertrophic osteoarthropathy. Case report. 779 60

Hypertrophic osteoarthropathy is an important manifestation of lung carcinoma, particularly in a non-small cell tumor, and hampers quality of life. Although removal of the primary tumor usually resolves this syndrome, effective treatment in patients with advanced lung carcinoma has not been established. Recently, an orally active, selective epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor ("Gefitinib") provided clinical anti-tumor activity. We describe a 71-year-old male smoker with cough, who presented with clubbed fingers. A transbronchial lung biopsy (stage T2N3M1-IV) on a cavity lesion in the left lower lobe showed the features of adenocarcinoma, while bone scintigram revealed bilaterally symmetrical abnormal uptakes in the lower extremities, suggesting secondary hypertrophic osteoarthropathy. The serum level of growth hormone was increased to 1.42 ng/ml. Chemotherapy (cisplatin, vinorelbine) was not effective. Gefitinib, as a second-line therapy, induced disappearance of the abnormal accumulation on bone scintigraphy and decrease of the cavity in the lung and of serum growth hormone. The presented case suggests that the EGFR inhibitor might be a promising option for the treatment of hypertrophic osteoarthropathy with advanced lung adenocarcinoma.
 ...
PMID:Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma. 1608 Apr 71

Hypertrophic osteoarthropathy (HOA) is a syndrome characterized by digital clubbing, arthralgias, and tissue swelling and is frequently described in association with bronchogenic carcinoma. The associated pain can be disabling, and symptoms are often resistant to conventional analgesic medications. We present a patient with HOA of the lower extremities and wrists that developed after bronchogenic carcinoma. The pain and swelling completely resolved after a single administration of 4 mg of zoledronic acid. The proposed pathogenesis of HOA and the mechanisms by which bisphosphonates might alleviate symptoms are reviewed.
Clin Lung Cancer 2008 May
PMID:Hypertrophic osteoarthropathy effectively treated with zoledronic acid. 1862 29

Numerous causes of hypertrophic osteoarthropathy (HOA) have been reported. Commonly, secondary osteoarthropathy accompanies pulmonary diseases such as carcinoma of the lung, pleural tumors, lung abscesses, and bronchiectasis. However, HOA in inflammatory bowel disease is a rare complication. There are only a few reports of secondary HOA with Crohn's disease. Our purpose was to report another case of HOA in Crohn's disease. We describe a case of a 27-year-old man with underlying Crohn's disease presenting with 2 years of pain in multiple joints. Radiographic findings suggested HOA in extremities. We performed a conservative treatment including medication and rehabilitations. The patient's symptoms were much improved at the latest follow-up. Although numerous studies on HOA have been published, the pathogenesis of HOA is still unclear. Various treatment modalities were recommended but further studies to uncover the pathogenesis of HOA with Crohn's disease and to establish a treatment modality are needed.
...
PMID:Hypertrophic osteoarthropathy in patient with Crohn's disease: a case report. 2502 1